Ireland· IE-PA-EU/1/99/117/003-004
Synagis 50 mg/0.5 ml and 100 mg/1 ml Solution for injection
A palivizumab product containing palivizumab, registered in Ireland by AstraZeneca AB. The same ATC class is registered in 2 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Palivizumab is registered in 2 of 19 countries.
Countries holding a registration under ATC J06BB16 (palivizumab), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 1 of them publish a price we can compare per daily dose
Palivizumab · ATC J06BB16
2 / 19 countries
- Belgiumprice
- Ireland
The record
At a glance
HPRA (Ireland)- Active substance
- Palivizumab
- Manufacturer
- AstraZeneca AB
- Country
- Ireland (IE)
- ATC code
- J06BB16
- ATC class
- Palivizumab
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/99/117/003-004
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Palivizumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandSynagis2care4 ApS
- FranceSYNAGIS 100 mg/ml, solution injectableASTRAZENECA AB
- United StatesSynagisSwedish Orphan Biovitrum AB (publ)
- NetherlandsSynagis 100 mg/ml, oplossing voor injectieAstraZeneca AB
- United KingdomSynagis 100mg powder and solvent for solution for injection vialsAbbVie Ltd
- BelgiumSynagis 100 mgAstraZeneca
- SpainSYNAGIS 100 mg POLVO Y DISOLVENTE PARA SOLUCION INYECTABLEAstrazeneca Ab
- NorwaySynagisAstraZeneca AB (2)
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Synagis
- Liechtenstein · Synagis
- Norway · Synagis
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/3e059ffb-4334-4fd5-b498-241642603b4d GET /v1/drugs/3e059ffb-4334-4fd5-b498-241642603b4d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection",
"routes": [
"Intramuscular use"
],
"source": "hpra",
"atc_all": [
"J06BB",
"J06BB16"
],
"strength": null,
"pa_number": "EU/1/99/117/003-004",
"substances": [
"Palivizumab"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "22/08/2014",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about palivizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.